Status:
WITHDRAWN
Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans
Lead Sponsor:
Auburn University
Collaborating Sponsors:
Tuscaloosa Veterans Affairs Medical Center
Conditions:
Pharmacogenetics
Depressive Disorder, Major
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
The purpose of this study is to assess the prevalence of veterans with major depressive disorder (MDD) who are being treated with a medication that has current Clinical Pharmacogenetics Implementation...
Eligibility Criteria
Inclusion
- Age ≥ 19 years
- Prescribed at least one chronic medication for mental health which is considered pharmacogenomically actionable, as defined above (amitriptyline, doxepin, imipramine, nortriptyline, citalopram, escitalopram, fluvoxamine, paroxetine, sertraline, or venlafaxine).
- Diagnosis of major depressive disorder (MDD)
Exclusion
- Subject is a prisoner or is under a court order for treatment as part of a sentence or incarceration
- Persistent medication non-adherence for reasons not potentially linked to pharmacogenomic variation (e.g. inability to obtain medications due to cost; non-adherence due to cognitive impairment)
- Individuals receiving mental health treatment/care from a non-VA facility
- Individuals who are terminally ill
- Inability to communicate in and/or understand English
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04893395
Start Date
September 1 2021
End Date
December 31 2022
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tuscaloosa VAMC
Tuscaloosa, Alabama, United States, 35404